DaVita (DVA) Stock Price, News & Analysis

Company Overview

DaVita Inc. (NYSE:DVA) is a leading provider of kidney care services, specializing in outpatient dialysis for patients suffering from chronic kidney disease and end stage renal disease (ESRD). Headquartered in Denver, Colorado, the company operates a network of more than 2,800 outpatient dialysis centers across the United States, delivering hemodialysis and peritoneal dialysis treatments. DaVita’s portfolio also includes a range of supportive services such as vascular access management, laboratory diagnostics and nutritional counseling, all designed to optimize patient outcomes and quality of life.

In addition to its core in-center dialysis operations, DaVita offers comprehensive home dialysis solutions. Through its Home Therapies program, patients can choose daily home hemodialysis or peritoneal dialysis, supported by training, remote monitoring and specialized equipment. The company has invested in technology platforms and water purification systems to ensure treatment efficacy and safety, and it continues to explore telehealth innovations and mobile care units to extend access in underserved areas.

Founded in 1999 following a management-led buyout of the dialysis business of a major healthcare provider, DaVita traces its roots to pioneering efforts in the late 1970s to deliver outpatient renal therapy. Over the years, it has expanded beyond the U.S. into select international markets, including parts of Europe, Latin America and Asia Pacific, often forming partnerships with local hospitals and health systems to adapt its care model to regional regulations and patient needs.

DaVita is led by President and Chief Executive Officer Javier Rodriguez, who joined the company in 2016 and has held senior leadership roles spanning finance and operations. Under his guidance, DaVita has focused on patient-centered clinical programs, community outreach initiatives and strategic collaborations, positioning itself as a trusted provider in the evolving landscape of kidney care.

Key Stats

• Today's Range: $141.84 to $144.06
• 50-Day Range: $134.44 to $146.77
• 52-Week Range: $131.76 to $179.60
• Volume: 600,082 shs
• Average Volume: 809,316 shs
• Market Capitalization: $10.76 billion
• P/E Ratio: 14.13
• Dividend Yield: N/A
• Price Target: $164.50
• Consensus Rating: Hold

DaVita Stock Analysis - MarketRank™

DaVita scored higher than 86% of companies evaluated by MarketBeat, and ranked 442nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

DaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

DaVita has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 18.12%

Earnings Growth

Earnings for DaVita are expected to grow by 18.12% in the coming year, from $10.76 to $12.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DaVita is 14.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of DaVita is 14.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

Price to Earnings Growth Ratio

DaVita has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

DaVita has a P/B Ratio of 29.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.65% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in DaVita has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DaVita does not currently pay a dividend.

Dividend Growth

DaVita does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.06

Percentage of Shares Shorted

8.65% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in DaVita has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.31

News Sentiment

DaVita has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for DaVita this week, compared to 12 articles on an average week.

Search Interest

Only 3 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added DaVita to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DaVita insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.00% of the stock of DaVita is held by insiders.

Percentage Held by Institutions

90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVA Stock Analysis - Frequently Asked Questions

How have DVA shares performed this year?

DaVita's stock was trading at $149.55 at the start of the year. Since then, DVA stock has decreased by 4.7% and is now trading at $142.56.

How were DaVita's earnings last quarter?

DaVita Inc. (NYSE:DVA) released its earnings results on Monday, May, 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The firm's quarterly revenue was up 5.0% on a year-over-year basis.
Read the conference call transcript.

Does DaVita have any subsidiaries?

The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and more.

How do I buy shares of DaVita?

Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DaVita own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:DVA
• CIK: 927066
• Web: www.davita.com
• Phone: (720) 631-2100
• Fax: 302-636-5454
• Employees: 76,000
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $164.50
• High Stock Price Target: $184.00
• Low Stock Price Target: $145.00
• Potential Upside/Downside: +15.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.09
• Trailing P/E Ratio: 14.12
• Forward P/E Ratio: 13.24
• P/E Growth: 1.01
• Net Income: $936.34 million
• Net Margins: 6.63%
• Pretax Margin: 11.14%
• Return on Equity: 176.11%
• Return on Assets: 4.66%

Debt

• Debt-to-Equity Ratio: 23.18
• Current Ratio: 1.25
• Quick Ratio: 1.20

Sales & Book Value

• Annual Sales: $12.82 billion
• Price / Sales: 0.84
• Cash Flow: $18.58 per share
• Price / Cash Flow: 7.67
• Book Value: $4.83 per share
• Price / Book: 29.51

Miscellaneous

• Outstanding Shares: 75,500,000
• Free Float: 73,990,000
• Market Cap: $10.76 billion
• Optionable: Optionable
• Beta: 1.11